ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1350	National Cancer Institute	Html	en	Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult central nervous system tumors.	treatment 0.515559 malignant tumor cells 0.227722 general information 0.262069 NCI-supported cancer 0.222651 cancer cells 0.27674 type 0.244277 spinal cord tumors 0.473603 clinical trial search 0.391071 brain tumors 0.2801 spinal cord 0.914442 tumor cells 0.493038 normal cells 0.296092	clinical trial 0.432056 clinical trials 0.701078 brain tumor 0.235359 brain 0.738045 PDQ summary 0.285532 tumors 0.535252 cancer clinical trials 0.361596 tumor 0.77091 radiation therapy 0.479169 grade 0.218633 cancer 0.578346 information 0.296506	CLICK HERE
1473	National Cancer Institute	Html	en	Gallbladder Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gallbladder cancer.	similar median OS 0.628591 intact organ function 0.622839 PDQ cancer information 0.730699 extrahepatic bile duct 0.642047 standard surgical procedure 0.635592 Systemic chemotherapy 0.571595 lymphatic tissue 0.570673 biliary obstruction 0.585733 cancer information summary 0.709899 breast cancer prevention 0.628762 hematologic toxic effects 0.620759 delayed recurrences 0.576123 gallbladder cancer. 0.68322 median overall survival 0.632156 surgical specimen 0.573532 wedge resection 0.601072 liver tissue 0.572719 port sites 0.635991 single institution 0.570884 metastatic gallbladder cancer 0.742217 NCI’s PDQ 0.589794 NCI PDQ cancer 0.658789 lymph nodes 0.686365 consecutive surgical patients 0.660543	laparoscopic removal 0.566309 N2 lymph node 0.694743 gallbladder cancer 0.941749 transhepatic biliary drainage 0.640041 node positive tumors 0.650245 single-agent gemcitabine 0.568199 hepatoduodenal ligament 0.573622 surgical intervention. 0.574213 muscle layer 0.568687 routine gallbladder operation 0.744072 unsuspected cancer 0.606476 phase III study 0.612031 5-year survival 0.582018 advanced biliary cancers 0.636965 PDQ documents 0.58963 platinum agents 0.566154 gallbladder bed 0.684231 transient partial remissions 0.621529 node negative tumors 0.647847 adequate performance status 0.625607 unsuspected gallbladder cancer 0.785275 Long-term disease-free survival 0.641402 pathologic examination 0.580848 Kaplan-Meier estimates 0.57231	CLICK HERE
1754	National Cancer Institute	Html	en	Breast Reconstruction After Mastectomy	A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction.	breast reduction surgery 0.28849 tissue breast reconstruction 0.452019 flap reconstruction 0.330223 immediate reconstruction 0.31662 tissue 0.60196 breast reconstruction surgery 0.457163 mastectomy 0.359177 implant 0.307847 implant reconstruction 0.254395 breast numbness 0.249047 donor tissue 0.258639 breast skin 0.288491 early-stage breast cancer 0.279638 natural breast shape 0.273514 pedicled flap reconstruction 0.298564 autologous tissue reconstruction 0.366797 breast cancer experience 0.279508 reconstructed breast 0.419512 autologous reconstruction 0.246473 tissue expander 0.25279 blood vessels 0.426971 chest wall tissue 0.239092 entire breast 0.302278 Delayed reconstruction 0.247408 breast cancer therapy 0.323533	radiation therapy 0.283075 breast reconstruction technique 0.360333 breast forms 0.256638 external breast prostheses 0.334034 women 0.280496 surgical nipple reconstruction 0.280177 breast reconstruction method 0.374498 breast reconstruction 0.909174 breast rebuilt 0.281588 free flap reconstruction 0.325097 breast cancer recurrence 0.30156 woman considering breast 0.279422 breast tissue 0.318522 flap 0.344123 sufficient breast volume 0.289888 autologous tissue 0.583784 Breast Implants page 0.303495 breast surgeons 0.246995 breast area 0.280597 breast cancer 0.510147 skin-sparing mastectomy 0.235094 Breast Disease 0.251106 inflammatory breast cancer 0.289892 chest tissue 0.237416	CLICK HERE
1763	National Cancer Institute	Html	en	Anal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing anal cancer and about research aimed at the prevention of this disease.	HPV status 0.37901 high-grade AIN 0.400535 HIV-positive men 0.374588 persistent HPV-6 0.369098 receptive anal intercourse 0.461565 Squamous cell cancer 0.399212 vulvar cancer survivors 0.380555 anal cancer SIR 0.523735 situ cervical cancer 0.423387 vaccine efficacy 0.403995 invasive vulvar cancer 0.380408 anal cancer risk 0.726451 anal exposure 0.434477 control-arm participants 0.42062 invasive cervical cancer 0.389499 anal cancers 0.477855 anal cancer diagnosis 0.502826 aforementioned multicountry cohort 0.36576 anal specimen 0.431502 anal cancer development 0.479231 HIV-positive MSM 0.39967 HIV-positive individuals 0.372051 baseline HPV status 0.371352 Anal HPV infection 0.502008	cell anal cancer 0.613468 per-protocol analysis 0.375594 cervical cancer survivors 0.388113 invasive cervical cancer. 0.365873 CI 0.564521 anal intraepithelial neoplasia 0.498397 oncogenic HPV strains 0.395201 anal infection 0.44494 anal cancer 0.940209 incidence rate 0.454386 cervical cancer 0.429644 sexual practices 0.401313 intent-to-treat analysis 0.37619 anal specimens 0.430195 HPV vaccine regimen 0.379059 invasive vaginal cancer 0.37973 squamous cell anal 0.539127 high-grade squamous cell 0.379806 cervical cancer prevention 0.379871 standardized incidence ratio 0.365263 unprotected anal 0.440711 HIV infection 0.421202 HIV-positive women 0.373444	CLICK HERE
1781	National Cancer Institute	Html	es	Aflicción, duelo y manejo de la pérdida (PDQ®)–Versión para profesionales de salud	Informe revisado por expertos acerca de la aflicción, el duelo y los sentimientos de pérdida de los sobrevivientes de alguien que murió de cáncer. Se trata también la aflicción en los niños.	stage theory 0.267105 Maciejewski PK 0.231481 Stroebe MS 0.59893 Stroebe W 0.357559 Life after death 0.262032 recovery from bereavement 0.268449 practical approach 0.234785 Prigerson HG 0.312593 American Psychiatric 0.266127 querido experimentarán 0.250079 American Psychological Association 0.813443 anticipatory grief 0.242932 Basic Books 0.301434 doctors just suddenly 0.262469 expresión aflicción 0.53581 of bereavement 0.95448 Clin Psychol 0.275517 author reply 0.229064 Weiss RS 0.256177 OF BEREAVEMENT REACTIONS 0.235244 Abrahm J 0.230792 post-traumatic stress disorder 0.252503 normal grief 0.23971 Bonanno GA 0.370739 Rando TA 0.231119	aflicción crónica 0.899606 Psychol Rev 0.235309 hombres media 0.239089 aflicción —una estructura 0.407961 Kaltman S 0.233673 parkes cm 0.351633 Bowlby J 0.229028 stress disorder 0.261132 Publishing Company 0.2876 Kutner JS 0.233996 grief therapy 0.242395 Zisook S 0.24705 New York 0.577019 Pathologic Grief 0.292395 Intern Med 0.234619 Hansson RO 0.641388 Clin Psychiatry 0.231444 Volume III 0.230537 querido experimentarán períodos 0.229309 Springer Publishing Company 0.252277 BEREAVEMENT AND MENTAL 0.237671 Schut H 0.386829 Jacobs SC 0.300142 Casarett D 0.230099	CLICK HERE
2030	National Cancer Institute	Html	es	Exámenes de detección del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de mama.	carcinoma in situ 0.428206 Surgical Adjuvant Breast 0.33856 Breast Screening Study-2 0.364743 cohort with breast 0.321173 Breast Cancer Surveillance 0.36101 American Cancer Society 0.380459 ductal proliferative breast 0.324288 ductal carcinoma in 0.430875 breast biopsy 0.352636 Elmore JG 0.344418 Swedish two-county breast 0.320934 Breast Screening 0.503535 Breast Screening Study 0.375642 Rosenberg RD 0.33024 Kerlikowske K 0.327142 Nelson HD 0.325559 Canadian National Breast 0.417726 Individual Breast Biopsy 0.343511 evaluación bi-rads 0.320008 Scotia Breast Screening 0.356932 breast pathology 0.332437 Estados Unidos 0.485991 screening mammograms 0.346351 Natl Cancer Inst 0.674282 Breast tumor characteristics 0.346186	mamografía detecta 0.320239 breast self-examination 0.321577 screening mammographic sensitivity 0.338051 National Breast Screening 0.456899 mamografía digital versus 0.325297 Breast Screening Program 0.356597 modern screening mammography 0.338726 Cancer Facts 0.328174 breast cancers 0.931042 Image-detected breast 0.320721 Breast Imaging Reporting 0.320397 screening mammography 0.509779 Breast Biopsy Slides 0.344265 screening trial 0.341724 mammographic screening 0.329483 Carney PA 0.325142 Intern Med 0.487403 Breast symptoms among 0.322392 Arch Intern Med 0.323503 clinical breast 0.339712 mammographic screening from 0.319885 in situ 0.62536 Cancer Surveillance Consortium 0.332496 Nova Scotia Breast 0.339428	CLICK HERE
15487	National Cancer Institute	Html	en	Seeking Cancer Clues in Blood, Researchers Explore Exosomes	A feature-length Research Update article about exploring ways to use vesicles known as exosomes to develop new clinical tests and tools for patients with cancer.	Dr. Alvarez 0.382039 exciting preliminary study 0.288255 Hector Alvarez 0.230222 organ-specific metastases 0.263438 research 0.34419 unneeded proteins 0.218149 cancer-associated genetic alterations 0.292328 Ph.D. 0.232319 reliable diagnostic biomarkers 0.286894 pancreatic tumors 0.316162 tumor-derived exosomes 0.435098 liver metastases 0.261607 distant sites 0.270026 David Lyden 0.230954 potential source 0.27056 potentially debilitating surgery 0.288289 researchers 0.33374 exosomal DNA 0.235697 generally reliable source 0.276449 ultimate goal 0.288377 liquid biopsy tests 0.276523 Dr. Lyden 0.452577 cell-free DNA 0.302958 Weill Cornell Medicine 0.277332 coauthor Bruno Costa-Silva 0.277568	different cells 0.270221 exosome-derived DNA 0.320829 potential clinical application 0.294125 primary cancer 0.228119 lung metastases 0.261657 cancer cells 0.736815 accompanying editorial 0.30439 Trinity College Dublin 0.290697 primary tumor cells 0.384123 release exosomes 0.30546 originating cells 0.294925 high-quality DNA 0.233017 metastases 0.284855 distant locations 0.221908 diagnostic blood test 0.298912 exosomes 0.914671 Cancer Research 0.263148 pancreatic cancer cells 0.436342 specific cells 0.275707 MD Anderson Cancer 0.353274 clinical tools 0.317657 breast cancer 0.228037 genetic changes 0.218672 tumor DNA 0.385381	CLICK HERE
15650	National Cancer Institute	Html	en	Step 2: Application Receipt & Assignment	Information on the assignment numbers the Center for Scientific Review (CSR) creates once an application is submitted and other submission policies.	Application Type 0.237536 100,228th application 0.228911 program director 0.554123 peer review process 0.902016 initial peer review 0.326681 Scientific Review 0.216004 new application 0.239088 specific application 0.226573 Resubmission Applications 0.206964 research grant applications 0.359218 his/her assigned application 0.489157 specific budgetary limits 0.31822 Program Announcements 0.201839	pre-announced Request 0.201939 appropriate application form 0.353459 new grant 0.218872 NIH peer review 0.369648 Incomplete applications 0.208003 NCI program director 0.428336 suffix code 0.378185 grant numbers 0.228139 application 0.702093 NIH Policy 0.353037 traditional research project 0.330544 central receipt point 0.406816	CLICK HERE
16830	National Cancer Institute	Html	en	Clinical Trial Sequencing Project	null	gene expression test 0.968523 vital genomic information 0.445867 non-metastatic RCC 0.377128 breast cancer response 0.478667 Large B Cell 0.384272 NCTN clinical trials 0.448807 ECOG-ACRIN E2805 trial 0.421922 DLBCL patients 0.352651 National Clinical Trials 0.46574 molecular basis 0.431838 advanced RCC 0.374566 clinical trials 0.533121 VEGF inhibitors 0.375945 clinical trial 0.642586 RCC development 0.370697 breast cancer patients 0.519364 comprehensive molecular analysis 0.404401 Genomic Data Commons 0.460933 Trial Assigning Individualized 0.463121 cancer types 0.360865 surgical removal 0.412464 chemotherapy best complements 0.471441 large B-cell lymphoma 0.45172 cancer recurrence 0.405985 low-risk patients 0.363667	clinically helpful tool 0.4004 rich molecular data 0.400698 Combination Chemotherapy 0.375651 cancer research community 0.644574 adult non-Hodgkin lymphoma 0.414301 Her2-negative breast cancer 0.645596 NCI-sponsored clinical trial 0.620071 common kidney cancer 0.437411 endothelial growth factor 0.403689 different chemotherapy regimens 0.474741 human epidermal growth 0.418539 anonymized clinical data 0.446701 genomic alterations 0.360205 CCG 0.375478 NCI-sponsored clinical trials 0.472546 pathway drives RCC 0.461359 breast cancer 0.780189 best individualized treatment 0.43596 Clinical Trial Sequencing 0.508554 tissue samples 0.518757 breast cancer treatments 0.478341 renal cell carcinoma 0.625007 New England Journal 0.405702 Diffuse Large 0.405055	CLICK HERE
17285	National Cancer Institute	Html	en	Cognitive Impairment in Adults with Non?Central Nervous System Cancers (PDQ®)–Health Professional Version	Expert-reviewed information summary about cognitive impairment in cancer patients versus normal cognition, and interventions to manage cognition changes	baseline cognitive reserve 0.507261 Cognitive changes 0.487133 adjuvant chemotherapy 0.565287 cancer treatment 0.487264 female breast cancer 0.505802 healthy control subjects 0.489493 Evidence-based cognitive rehabilitation 0.50091 Primary Breast Cancer 0.514885 Advanced cognitive training 0.507364 Clin Breast Cancer 0.579754 cognitive disturbance 0.483538 therapy-related cognitive deficits 0.504332 Eur J Cancer 0.484911 early-stage breast cancer 0.528107 cognitive dysfunction 0.521546 Von Ah 0.50591 cognitive function 0.609612 cancer-related cognitive impairment 0.500166 cognitive problems. 0.495567 breast cancer patients 0.582272 cancer patients 0.586019 elderly cancer patients 0.495074 cognitive functioning 0.510209 breast cancer survivors 0.779751 self-reported cognitive complaints 0.520137	cancer survivors 0.787075 cancer chemotherapy 0.497699 et al. 0.681052 psychosocial cancer rehabilitation 0.489752 colorectal cancer survivors 0.495325 cognitive rehabilitation 0.534264 PUBMED Abstract 0.565725 Support Care Cancer 0.521007 chemotherapy-treated breast cancer 0.517795 self-reported cognitive dysfunction 0.498525 experience cognitive problems 0.520232 cognitive impairment. 0.494247 Abstract 0.636513 Clin Oncol 0.48687 breast cancer 0.95028 group cognitive rehabilitation 0.514826 elderly cancer survivors 0.500464 randomized controlled trial 0.590229 Cognitive rehabilitation group 0.513937 treatment-related cognitive impairment 0.499304 brain tumor patients 0.525127 chemotherapy-related cognitive change 0.538912 cognitive impairment 0.555272 self-reported cognitive problems 0.505428	CLICK HERE